Videra Health vs Wysa

For a program choosing a tool for crisis risk, Wysa is the weaker pick. A third-party summary of Wysa's FAQ says the app is not designed for crisis intervention, and the same third-party listing credits Wysa with SOS detection and helpline signposting. Videra's home page claims a 64% reduction in crisis-driven interventions, a vendor figure.

Videra Health gets shortlisted for depression, anxiety and PTSD screening. The vendor says Assess can predict PHQ-9, GAD-7 and PCL-5 scores from as little as one minute of input, and it reports an AUC of 0.87 to 0.92 for its tardive dyskinesia video model. The 2026 JMIR Mental Health cross-dataset validation study was written by Videra and also lists external clinician co-authors. Pricing follows a demo.

Wysa suits a health system or NHS Talking Therapies service that wants an anonymous CBT-based chat in patients' hands. Videra's pages describe no patient-facing chat. Third-party sources put consumer Premium at $74.99 per year while the App Store US listing shows $99.99, and organizations get custom quotes. The FDA's May 2022 Breakthrough Device Designation covers chronic musculoskeletal pain with depression and anxiety and is not a clearance. Many authors on Wysa's own evidence list, a chronic-disease RCT among them, are company-affiliated.